Quantcast

Latest hyperphosphatemia Stories

2014-08-06 12:29:28

Nephrologists Seem More Confident That an Iron-Based Phosphate Binder Will Impact the Use of IV Iron vs. the Use of ESAs, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 6, 2014 /PRNewswire/ -- Decision Resources Group finds that there is a high need for new phosphate binders to treat hyperphosphatemia among surveyed U.S. nephrologists (n=102). Phosphate binders with fewer pills, better efficacy in reducing serum phosphorous and improved tolerability are rated as...

2014-07-10 12:28:45

Interest in GCS-100, Velcalcetide, ST-10, GSK-1278863A and Rayaldee Ranges from Moderate to High, According to Findings from Decision Resources Group BURLINGTON, Mass., July 10, 2014 /PRNewswire/ -- Decision Resources Group finds that over half of surveyed nephrologists report awareness of the U.S. Food and Drug Administration's (FDA) approval of Vifor Fresenius Medical Care Renal Pharma's new phosphate binder Velphoro, which was approved by the FDA in November 2013 for the treatment of...

2014-05-15 08:32:20

Study will evaluate tenapanor for the treatment of hyperphosphatemia in ESRD patients on hemodialysis FREMONT, Calif., May 15, 2014 /PRNewswire/ -- Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced that it has received a $25 million milestone payment from AstraZeneca (NYSE:AZN, LON:AZN) for the initiation of a Phase 2b clinical trial evaluating tenapanor for the treatment of hyperphosphatemia, or elevated...

2014-02-19 08:32:28

LONDON, Feb. 19, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) - Opportunity Analysis and Forecasts to 2017 OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) - Opportunity Analysis and Forecasts to 2017 Summary Late-stage chronic kidney disease (CKD), encompassing stage 4 and 5 CKD, is a disease that manifests in a host of co-morbidities. Of these, bone and mineral...

2014-01-17 08:23:10

Marketing Approval Triggers Milestone Payment to Keryx NEW YORK, Jan. 17, 2014 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that its Japanese partner, Japan Tobacco Inc. (JT), has received manufacturing and marketing approval of ferric citrate from the Japanese Ministry of Health, Labour and Welfare. Ferric citrate, to be marketed in Japan by JT's subsidiary, Torii Pharmaceutical Co., Ltd., under the brand name Riona(®), is indicated as an oral...

2013-09-10 23:27:21

Approval of This Novel Phosphate Binder Will Be a Major Milestone for the Company Cary, NC (PRWEB) September 10, 2013 BioLink Life Sciences, Inc., a biopharmaceutical innovator, announced today that the U.S. Food & Drug Administration (FDA) has accepted its New Drug Application for PiLo™ (calcium succinate capsules) for review. PiLo™ is the Company's patented phosphate binder for the treatment of elevated blood phosphate in patients with end stage renal disease (ESRD). Upon...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related